We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.59%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-10.58%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$947K |
| 2 |
Moderna
MRNA
|
+$899K |
| 3 |
Meta Platforms (Facebook)
META
|
+$895K |
| 4 |
Netflix
NFLX
|
+$876K |
| 5 |
Chipotle Mexican Grill
CMG
|
+$852K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$1.01M |
| 2 |
Progressive
PGR
|
+$999K |
| 3 |
Stryker
SYK
|
+$984K |
| 4 |
Republic Services
RSG
|
+$973K |
| 5 |
Linde
LIN
|
+$966K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Precigen
PGEN
$1.93B
| $101K | 0.06% |
87,692
+28,522
| +48% | +$33.7K |
|
|
IGMS
377
DELISTED
IGM Biosciences
IGMS
| $101K | 0.06% |
10,896
+5,783
| +113% | +$64.8K |
|
378
Kura Oncology
KURA
$901M
| $100K | 0.06% |
9,480
+1,795
| +23% | +$21.2K |
|
379
Lyell Immunopharma
LYEL
$318M
| $100K | 0.06% |
1,576
+155
| +11% | +$8.58K |
|
380
Cogent Biosciences
COGT
$6.91B
| $100K | 0.06% |
8,462
+95
| +1% | +$1.09K |
|
381
Caribou Biosciences
CRBU
$158M
| $99.8K | 0.06% |
23,486
+11,087
| +89% | +$49.8K |
|
382
Atea Pharmaceuticals
AVIR
$386M
| $99.4K | 0.06% |
26,586
+3,638
| +16% | +$13.6K |
|
383
Cullinan Oncology
CGEM
$1.07B
| $99.4K | 0.06% |
9,239
+756
| +9% | +$8.03K |
|
384
TG Therapeutics
TGTX
$8.53B
| $99.4K | 0.06% |
4,001
-7,053
| -64% | -$182K |
|
|
PNT
385
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $99.1K | 0.06% |
10,939
-3,963
| -27% | -$35K |
|
386
Nurix Therapeutics
NRIX
$2.43B
| $99K | 0.06% |
9,912
+1,731
| +21% | +$17.7K |
|
|
RNAM
387
DELISTED
Avidity Biosciences
RNAM
| $98.9K | 0.06% |
8,920
+2,989
| +50% | +$37.5K |
|
388
Denali Therapeutics
DNLI
$3.74B
| $98.8K | 0.06% |
3,349
+56
| +2% | +$1.57K |
|
389
Dyne Therapeutics
DYN
$4.24B
| $98.7K | 0.06% |
8,769
+1,434
| +20% | +$16.9K |
|
390
Krystal Biotech
KRYS
$10.4B
| $98.6K | 0.06% |
840
-466
| -36% | -$47.6K |
|
391
Disc Medicine
IRON
$2.85B
| $98.5K | 0.06% |
+2,219
| New | +$78.7K |
|
392
Xenon Pharmaceuticals
XENE
$6.36B
| $98.3K | 0.06% |
2,552
-58
| -2% | -$2.31K |
|
|
KRTX
393
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $98.2K | 0.06% |
453
-44
| -9% | -$9.43K |
|
394
Celldex Therapeutics
CLDX
$2.8B
| $98.1K | 0.06% |
2,892
+379
| +15% | +$12.8K |
|
395
Intellia Therapeutics
NTLA
$1.49B
| $98.1K | 0.06% |
2,406
-204
| -8% | -$8.27K |
|
396
Madrigal Pharmaceuticals
MDGL
$12.7B
| $97.9K | 0.06% |
424
-1,309
| -76% | -$355K |
|
397
Arcutis Biotherapeutics
ARQT
$3.48B
| $96.9K | 0.06% |
10,172
+4,084
| +67% | +$45.3K |
|
398
Kymera Therapeutics
KYMR
$9.05B
| $96.9K | 0.06% |
4,215
+796
| +23% | +$22.8K |
|
399
Immunovant
IMVT
$8.23B
| $96.9K | 0.06% |
5,107
-1,594
| -24% | -$29.7K |
|
|
ALLK
400
DELISTED
Allakos
ALLK
| $96.8K | 0.06% |
22,191
+7,756
| +54% | +$34.9K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, Virtus ETF Advisers held 495 positions worth $169M, down 7.2% from $182M the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Virtus ETF Advisers withdrew a net $17.8M in Q2 2023, closing 60 positions and reducing 257 holdings. Its most notable exit was Activision Blizzard, an estimated $1.01M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in NVIDIA worth $1.21M.
- Virtus ETF Advisers's largest Q2 2023 buy was NVIDIA: 28,520 shares worth $1.21M.
- Virtus ETF Advisers added most to Moderna in Q2 2023, an estimated $899K increase.
- Virtus ETF Advisers's biggest Q2 2023 reduction was Dow Inc, cutting an estimated $898K.
- Virtus ETF Advisers fully exited Activision Blizzard in Q2 2023, selling an estimated $1.01M.
- Virtus ETF Advisers's ten largest holdings make up 6.3% of its $169M portfolio in Q2 2023.
- Virtus ETF Advisers opened 55 new positions and closed 60 in Q2 2023.
- Virtus ETF Advisers's portfolio value fell 7.2% quarter-over-quarter to $169M.
Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.